M Rabaglio1, Z Sun2, K N Price3, M Castiglione-Gertsch4, H Hawle4, B Thürlimann5, H Mouridsen6, M Campone7, J F Forbes8, R J Paridaens9, M Colleoni10, T Pienkowski11, J-M Nogaret12, I Láng13, I Smith14, R D Gelber15, A Goldhirsch16, A S Coates17. 1. IBCSG Coordinating Center and Inselspital, Bern, Switzerland. Electronic address: manuela.rabaglio@ibcsg.org. 2. IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA. 3. IBCSG Statistical Center and Frontier Science and Technology Research Foundation, Boston, MA, USA. 4. IBCSG Coordinating Center, Bern. 5. Senology Center of Eastern Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Kantonsspital, St Gallen, Switzerland, Swiss Group for Clinical Cancer Research (SAKK). 6. Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark. 7. Institut du Cancer Nantes Atlantique, CLCC René Gauducheau, Saint Herblain, Fédération Nationale des Centres de Lutte Contre le Cancer, France. 8. Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calvary Mater Newcastle, Newcastle, New South Wales, Australia. 9. Department of Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium. 10. Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. 11. Cancer Center Maria Sklodowska-Curie Memorial Institute of Oncology, Warsaw, Poland. 12. Department of Mammary and Pelvic Surgery, Jules Bordet Institute; Brussels, Belgium. 13. Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary. 14. Breast Unit, The Royal Marsden Hospital, London, UK. 15. IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard School of Public Health and Harvard Medical School, Boston, MA, USA. 16. Department of Medicine, European Institute of Oncology, Milan, Italy; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 17. International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years ofadjuvant tamoxifen or letrozolefor endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial. METHODS: We evaluated 4895 patients allocated to 5 years ofletrozole or tamoxifen in the BIG 1-98 trial who received at least some study medication (median follow-up 60.3 months). Bone fracture information (grade, cause, site) was collected every 6 months during trial treatment. RESULTS: The incidence of bone fractures was higher among patients treated with letrozole [228 of 2448 women (9.3%)] versus tamoxifen [160 of 2447 women (6.5%)]. The wrist was the most common site of fracture in both treatment groups. Statistically significant risk factors for bone fractures during treatment included age, smoking history, osteoporosis at baseline, previous bone fracture, and previous hormone replacement therapy. CONCLUSIONS: Consistent with other trials comparing aromatase inhibitors to tamoxifen, letrozole was associated with an increase in bone fractures. Benefits of superior disease control associated with letrozole and lower incidence of fracture with tamoxifen should be considered with the risk profile for individual patients.
RCT Entities:
BACKGROUND: To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial. METHODS: We evaluated 4895 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial who received at least some study medication (median follow-up 60.3 months). Bone fracture information (grade, cause, site) was collected every 6 months during trial treatment. RESULTS: The incidence of bone fractures was higher among patients treated with letrozole [228 of 2448 women (9.3%)] versus tamoxifen [160 of 2447 women (6.5%)]. The wrist was the most common site of fracture in both treatment groups. Statistically significant risk factors for bone fractures during treatment included age, smoking history, osteoporosis at baseline, previous bone fracture, and previous hormone replacement therapy. CONCLUSIONS: Consistent with other trials comparing aromatase inhibitors to tamoxifen, letrozole was associated with an increase in bone fractures. Benefits of superior disease control associated with letrozole and lower incidence of fracture with tamoxifen should be considered with the risk profile for individual patients.
Authors: Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-01-02 Impact factor: 44.544
Authors: Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang Journal: Lancet Date: 2005 Aug 6-12 Impact factor: 79.321
Authors: Edith A Perez; Robert G Josse; Kathleen I Pritchard; James N Ingle; Silvana Martino; Brian P Findlay; Tamara N Shenkier; Richard G Tozer; Michael J Palmer; Lois E Shepherd; Shifang Liu; Dongsheng Tu; Paul E Goss Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: P Hadji; J-J Body; M S Aapro; A Brufsky; R E Coleman; T Guise; A Lipton; M Tubiana-Hulin Journal: Ann Oncol Date: 2008-04-29 Impact factor: 32.976
Authors: Paul E Goss; James N Ingle; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Dongsheng Tu Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: Stephen E Jones; James Cantrell; Svetislava Vukelja; John Pippen; Joyce O'Shaughnessy; Joanne L Blum; Robert Brooks; Nicole L Hartung; Angel G Negron; Donald A Richards; Ragene Rivera; Frankie Ann Holmes; Sreeni Chittoor; Thomas L Whittaker; James H Bordelon; Steven J Ketchel; Jennifer C Davis; Des Ilegbodu; Jean Kochis; Lina Asmar Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan S Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley J Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per E Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde Journal: N Engl J Med Date: 2004-03-11 Impact factor: 91.245
Authors: Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard Gelber; Stephan B Edge; Julie Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield Journal: J Clin Oncol Date: 2004-11-15 Impact factor: 44.544
Authors: R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi Journal: Osteoporos Int Date: 2012-01-20 Impact factor: 4.507
Authors: T Ponnapakkam; R Katikaneni; T Nichols; G Tobin; J Sakon; O Matsushita; R C Gensure Journal: J Endocrinol Invest Date: 2011-07-12 Impact factor: 4.256
Authors: Landry K Kamdem; Jingyue Xi; Brandi L Clark; Bryana J Gregory; Kelley M Kidwell; Ana-Maria Storniolo; Vered Stearns; Daniel F Hayes; Christina L Gersch; James M Rae; N Lynn Henry; Daniel L Hertz Journal: Breast Cancer Res Treat Date: 2019-02-12 Impact factor: 4.872
Authors: Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: Mohan Liu; Paul E Goss; James N Ingle; Michiaki Kubo; Yoichi Furukawa; Anthony Batzler; Gregory D Jenkins; Erin E Carlson; Yusuke Nakamura; Daniel J Schaid; Judy-Anne W Chapman; Lois E Shepherd; Matthew J Ellis; Sundeep Khosla; Liewei Wang; Richard M Weinshilboum Journal: Mol Endocrinol Date: 2014-08-22